DrugBank

AUGUST 20, 2024

The world of drug discovery is in a state of transformation, with advancements in biotechnology opening doors to new possibilities for targeting previously "undruggable" disease mechanisms. We also explore why some disease-associated targets remain elusive and how recent innovations are changing that narrative.

Therapies 71

Therapies Pharmaceuticals Disease Research 71

Plenge Gen

APRIL 7, 2020

You can download a pdf copy of the blog here.) Pharmacologic intervention has the opportunity to impact disease progression in the SARS-CoV-2 / COVID-19 crisis. … The post Drug repurposing in SARS-CoV-2 / COVID-19: preventing the maladaptive immune response leading to critical disease requiring ICU care.

Immune Response 52

Immune Response Disease Clinical Trials Drugs 52

The Pharma Data

OCTOBER 27, 2020

Stargardt disease is a devastating genetic disorder that affects central vision with no approved treatment options. . “This designation permits reVision to further accelerate the development of our Stargardt disease treatment. . RIDGEWOOD, N.J. , 28, 2020 /PRNewswire/ — ReVision Therapeutics, Inc.,

Disease 52

Disease Treatment FDA Licensing 52

Drug Channels

FEBRUARY 6, 2024

Access USA will unite PAP – Patient Assistance & Access Programs, Hub and Specialty Pharmacy Models East and the Rare Disease Summit three influential access conferences under one roof for one week of collaborative discussions and opportunities to expand your network and establish powerful partnerships. What is Access USA?

Specialty Pharmacies 40

Specialty Pharmacies Pharmacy Pharma Companies Disease 40

The Pharma Data

JANUARY 27, 2021

HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with Myasthenia Gravis (MG). CAMBRIDGE, Mass. ROTTERDAM, Netherlands and SUZHOU, China , Jan. ” he added.

Therapies 52

Therapies Treatment International Licensing 52

The Pharma Data

OCTOBER 14, 2020

“We look forward to continuing to advance apraglutide and to preparing our organization to bring a potential best-in-class therapy to people living with SBS.” . BASEL, Switzerland , Oct. chief executive officer of VectivBio. managing director at Versant Ventures and chairman of the board of directors at VectivBio.

Disease 52

Disease Treatment Therapies Production 52

The Pharma Data

SEPTEMBER 17, 2020

17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. INDIANAPOLIS and THOUSAND OAKS, Calif.

Therapies 52

Therapies Production Government Disease 52

PPD

OCTOBER 12, 2023

Cell and gene therapies (CGTs) are one of the fastest growing areas in human therapeutics. Since chimeric antigen receptor T cell (CAR-T) therapy was first approved in 2017, there has been a marked increase of cell and gene therapy studies resulting in significant changes in the way diseases are treated as well as patient outcomes.

Laboratories 52

Laboratories Protein Expression Clinical Trials Pharmacokinetics 52

KIF1A

AUGUST 28, 2024

KIF1A.ORG’s Chief Science Officer Dr. Dylan Verden will provide an overview of current areas of KAND therapeutic… Tuesday, September 24, 2024 5:00 pm – 6:00 pm Online via Zoom [link] ASO therapy: Positive Clinical Outcomes Observed We are thrilled to announce the publication of the **first-ever KAND ASO study** !

Therapies 52

Therapies Compound Screening Research Treatment 52

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

JANUARY 18, 2021

Potential first-in-class disease-modifying biologic in late-stage clinical studies. a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP.

Disease 52

Disease Science Clinical Development Treatment 52

The Pharma Data

AUGUST 7, 2020

As the pharma industry stands firm in its commitment to advance the sector to fight Covid-19, news has emerged from the European Commission who intend to streamline the development of therapies using genetically modified organisms to treat Covid-19. Regenerative medicine and advanced therapies thriving despite Covid-19 disruption.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

MAY 16, 2021

Description: John Coleman, ND, was diagnosed with Stage IV Parkinson’s Disease in 1995. John Coleman ND talks about how he recovered from Parkinson’s Disease in his pioneering book Stop Parkin’ and Start Livin’ He is the first to say there is no cure for Parkinson’s. No magic bullet exists. Others were.

Production 52

Production Disease Therapies International 52

KIF1A

FEBRUARY 29, 2024

Dear KAND Community, Happy Rare Disease Day! Today we are celebrating our collective strength and numbers within our KAND community and with all rare diseases globally. Download and read the research flyer for more details and scan the QR code to fill out the interest form. If we all standup and be counted, we will be heard!

Disease 52

Disease International Science Treatment 52

The Pharma Data

AUGUST 19, 2020

(Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 Nipocalimab recently received a rare pediatric disease designation from the U.S. Food and Drug Administration. An estimated 2.5

Disease 40

Disease Pharmaceuticals Treatment Pharmaceutical Companies 40

The Pharma Data

MAY 4, 2021

Baricitinib is an oral medication currently registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Test patients for latent TB before initiating Olumiant and during therapy.

Licensing 40

Licensing Licensing Therapies Laboratories 40

Perficient: Drug Development

OCTOBER 5, 2023

These disabilities can be the result of various factors, including developmental disorders, acquired brain injuries, neurodegenerative diseases, and more. Sensory Processing Therapy : Offers a range of sensory-based activities and exercises to improve sensory processing skills.

Regulations 52

Regulations Therapies Production Disease 52

The Pharma Data

DECEMBER 9, 2020

The targeted indication is for treatment of adult and paediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The following files are available for download: View original content: [link].

FDA Approval 40

FDA Approval Therapies FDA Treatment 40

The Pharma Data

NOVEMBER 25, 2020

CAN10 has been designed to block the signalling of the inflammatory cytokines IL-1, IL-33 and IL-36 resulting in unique properties for treatment of inflammatory diseases. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. About BioInvent. Cantargia AB (publ), reg.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

MAY 4, 2021

Amid the coronavirus pandemic, concern has grown over the potential neglect of other serious diseases. Multiple sclerosis (MS), for example, is a condition for which timely diagnosis, early treatment and the development of innovative therapies are particularly important for reducing the disabling progress of the disease.

Disease 52

Disease Treatment Therapies Vaccine 52

KIF1A

OCTOBER 3, 2024

Her leadership and vision have resulted in the establishment of crucial research initiatives, including a vision study and a speech study, alongside the development of gene therapy approaches and biomarkers specifically for KAND. KIF1A.ORG-Impact-report-2024_MCRI Download Congratulations Dr. Chung!

Small Molecule 52

Small Molecule Research Treatment Therapies 52

PerkinElmer

JUNE 7, 2021

Targeted cancer therapy has been a game changer in cancer treatment, significantly improving the survival and quality of life of many patients. Unlike chemotherapy, which acts on both cancer and normal cells, targeted therapy affects only the specific oncogenes, tumor suppressor genes, or pathways involved in tumor progression.

Treatment 52

Treatment Clinical Trials Therapies Trials 52

The ChEMBL-og

MAY 13, 2021

This paper on the 'Identification of the Core Chemical Structure in SureChEMBL Patents' has recently been published by Maria Falaguera and Jordi Mestres, and the resulting data set is available to download from the SureChEMBL FTP site: [link]. As mentioned above, this data set can be downloaded from SureChEMBL. of the total molecules).

Small Molecule 52

Small Molecule Therapies Disease Drugs 52

Perficient: Drug Development

SEPTEMBER 26, 2023

These disabilities can be the result of various factors, including developmental disorders, acquired brain injuries, neurodegenerative diseases, and more. While traditional therapies and interventions have proven beneficial, technology, particularly brain training apps, offers a new dimension of support.

Production 52

Production Disease Therapies Research 52

The Pharma Data

NOVEMBER 19, 2020

Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins , Chief Executive Officer and President, will participate in a virtual fire side chat at the 3 rd Annual Evercore ISI HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 10:55 a.m. .

Clinical Trials 52

Clinical Trials Therapies Disease Trials 52

Codon

FEBRUARY 13, 2024

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. alone, according to the Centers for Disease Control and Prevention.

Therapies 118

Therapies DNA Virus Clinical Trials 118

The Pharma Data

JANUARY 22, 2021

Voclosporin follows the recent approval of belimumab by the FDA as new therapies indicated for lupus nephritis – both within the past month. Since lupus impacts people differently and can change over time, a multidisciplinary team approach is going to be key to ensuring better overall care and to minimizing end-stage kidney disease.”

Research 52

Research Treatment FDA Approval Disease 52

The Pharma Data

OCTOBER 20, 2020

CureLab’s partners in the region will test the efficacy of the company’s DNA-based products against cancers and non-cancerous diseases of chronic inflammation. “There are horrible diseases that are dominant in the GCC region and rarely seen in the West,” said Jihad Fakhreddine. BOSTON , Oct. Source link.

DNA 52

DNA Hospitals International Trials 52

The Pharma Data

JANUARY 13, 2021

Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA. . NEW YORK , Jan. MindMed Co-CEO J.R. ” Robert Barrow Bio : Mr. .”

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

JANUARY 20, 2021

21, 2021 /PRNewswire/ — Dynacure , a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today the appointment of Jean M. View original content to download multimedia: [link].

Treatment 52

Treatment Pharmaceuticals Drug Development Science 52

The Pharma Data

DECEMBER 1, 2020

IsoPlexis’ Single-Cell Intracellular Proteome solution has been recognized for its impact on the development of better targeted and edited therapies and its potential to innovate and accelerate medical research. View original content to download multimedia: [link]. BRANFORD, Conn. , BRANFORD, Conn. , SOURCE IsoPlexis.

Therapies 52

Therapies Disease Science Research 52

The Pharma Data

SEPTEMBER 11, 2020

While stories from news outlets indicate the peak of the infection has passed in most European countries, cases of the disease continue to rise in other parts of the world, especially Latin America and Africa. Covid-19 command center aims to accelerate clinical research by individual sponsors to combat disease.

Clinical Trials 52

Clinical Trials Pharma Companies Trials Hospitals 52

The Pharma Data

SEPTEMBER 16, 2020

along with members of Amgen ‘s clinical development team, will discuss the Phase 1 data being presented on the Company’s investigational half-life extended bispecific T-cell engager (BiTE ® ) immuno-oncology therapy targeting prostate-specific membrane antigen (PSMA). . View original content to download multimedia: [link].

Clinical Development 52

Clinical Development Therapies Disease Research 52

The Pharma Data

JANUARY 26, 2021

The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. The company’s lead drug candidate is a novel, targeted immuno-oncology gene therapy for the treatment of multiple cancers. View original content to download multimedia: [link]. Source link.

Therapies 52

Therapies Treatment Drugs Disease 52

Perficient: Drug Development

OCTOBER 5, 2023

These disabilities can arise from various factors, such as developmental disorders, acquired brain injuries, neurodegenerative diseases, and more. Conditions like attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, and traumatic brain injuries (TBI) are common examples of cognitive disabilities.

Production 52

Production Therapies Disease 52

The Pharma Data

OCTOBER 29, 2020

The data underscore Lilly’s commitment to providing medicines for dermatologic diseases that have high unmet need, including alopecia areata (AA). ” In March, the FDA granted Breakthrough Therapy designation to baricitinib for the treatment of AA based on positive Phase 2 results from BRAVE-AA1. INDIANAPOLIS , Oct.

Therapies 52

Therapies Treatment Disease Clinical Trials 52

The Pharma Data

JANUARY 4, 2021

The most recent data from the Surveillance, Epidemiology, and End Results Program (SEER) of the US National Cancer Institute (NCI) estimated 19,940 new cases of AML and 11,180 deaths from this disease in the United States in 2020. . SUZHOU, China and ROCKVILLE, Md. , 4, 2021 /PRNewswire/ — Ascentage Pharma (6855.HK),

FDA 40

FDA Therapies Drugs Treatment 40